ENSYSCE BIOSCIENCES, INC. Investing Cash Flow
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Investing Cash Flow of -$123.64 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-30
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $0.00.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2022-12-31 was $0.00.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2022-09-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2022-06-30 was $0.00.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$123.64K.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2022 was $4.50K.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2020 was $183.40M, a 1447.27% increase from fiscal 2019.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2019 was $11.85M, a 1313.50% increase from fiscal 2018.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 4 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$123.64K 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$123.64K 10-Q · filed 2025-11-14 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $4.50K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $4.50K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $4.50K 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | $4.50K 10-Q · filed 2023-05-15 | |||||
| 2021-03-31 | -$62.50K 10-Q · filed 2021-06-08 | $183.34M derived: sum of 2 quarters · filed 2021-06-08 | $537.18K derived: sum of 3 quarters · filed 2021-11-15 | $48.72M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-12-31 | $183.41M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-06-08 | $599.68K derived: sum of 2 quarters · filed 2021-11-15 | $48.78M derived: sum of 3 quarters · filed 2021-11-15 | $183.40M 10-K/A · filed 2021-06-08 | ||
| 2020-09-30 | -$182.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$134.63M derived: sum of 2 quarters · filed 2021-11-15 | -$3.69K 10-Q · filed 2021-11-15 | $182.84M 10-Q · filed 2020-11-09 | $11.23M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $48.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $182.80M 10-Q · filed 2020-08-07 | $194.03M derived: sum of 3 quarters · filed 2021-06-08 | $194.18M derived: sum of 4 quarters · filed 2021-06-08 | ||
| 2020-03-31 | $134.62M 10-Q · filed 2021-06-08 | $145.85M derived: sum of 2 quarters · filed 2021-06-08 | $146.00M derived: sum of 3 quarters · filed 2021-06-08 | $146.33M derived: sum of 4 quarters · filed 2021-06-08 | ||
| 2019-12-31 | $11.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-06-08 | $11.37M derived: sum of 2 quarters · filed 2021-06-08 | $11.70M derived: sum of 3 quarters · filed 2021-06-08 | $11.85M 10-K/A · filed 2021-06-08 | ||
| 2019-09-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $472.00K derived: sum of 2 quarters · filed 2020-11-09 | $623.20K 10-Q · filed 2020-11-09 | $985.98K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $479.20K 10-Q · filed 2020-08-07 | $841.98K derived: sum of 3 quarters · filed 2020-08-07 | $984.54K derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $151.20K 10-Q · filed 2020-05-07 | $513.98K derived: sum of 2 quarters · filed 2020-05-07 | $656.54K derived: sum of 3 quarters · filed 2020-05-07 | $928.37K derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $362.77K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $505.33K derived: sum of 2 quarters · filed 2020-03-10 | $777.17K derived: sum of 3 quarters · filed 2020-03-10 | $838.59K 10-K · filed 2020-03-10 | ||
| 2018-09-30 | $142.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $414.39K derived: sum of 2 quarters · filed 2019-11-07 | $475.81K 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $271.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $333.25K 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | $61.42K 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | -$200.00M 10-K/A · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |